Statements (102)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:disease
gptkb:neurodegenerative_diseases |
| gptkbp:affects |
motor neurons
both men and women cognitive function |
| gptkbp:associated_with |
gptkb:SOD1_gene_mutations
C9orf72 gene mutations FUS gene mutations TARDBP gene mutations |
| gptkbp:can_be_hereditary_in |
5 to 10% of cases
|
| gptkbp:can_be_sporadic_or |
familial
|
| gptkbp:can_lead_to |
respiratory failure
paralysis loss of independence |
| gptkbp:cause |
muscle weakness
degeneration of motor neurons death among neurological diseases |
| gptkbp:charity |
gptkb:Ice_Bucket_Challenge
gptkb:ALS_Awareness_Month gptkb:Walk_to_Defeat_ALS |
| gptkbp:clinical_trial |
ongoing
phase 3 trials gene therapy trials drug trials stem cell trials |
| gptkbp:color |
purple
|
| gptkbp:condition |
requires multidisciplinary care
affects daily living activities can be emotionally challenging can lead to emotional distress has no known cure requires support from caregivers |
| gptkbp:diagnosis |
clinical examination
nerve conduction studies electromyography |
| gptkbp:first_described_by |
gptkb:Jean-Martin_Charcot
1869 |
| gptkbp:has_a_focus_on |
clinical trials
|
| gptkbp:has_research_focus |
gptkb:ALS_Therapy_Development_Institute
gptkb:ALS_Association gptkb:MDA |
| https://www.w3.org/2000/01/rdf-schema#label |
ALS
|
| gptkbp:impact |
quality of life
emotional distress financial burden loss of independence loss of mobility loss of speech |
| gptkbp:included |
the ALS Association's mission
|
| gptkbp:is_a_subject_of |
gptkb:medical_research
public awareness campaigns |
| gptkbp:is_associated_with |
environmental factors
genetic mutations viral infections toxic exposures |
| gptkbp:is_characterized_by |
muscle atrophy
spasticity progressive degeneration bulbar symptoms |
| gptkbp:is_common_in |
people aged 40 to 70
|
| gptkbp:is_involved_in |
gptkb:local_chapters
online forums patient advocacy groups caregiver support |
| gptkbp:is_managed_by |
physical therapy
occupational therapy speech therapy |
| gptkbp:is_often_discussed_in |
gptkb:literature
|
| gptkbp:is_often_seen_in |
gptkb:myasthenia_gravis
gptkb:muscular_dystrophy gptkb:multiple_sclerosis |
| gptkbp:is_often_treated_by |
neurologists
|
| gptkbp:is_recognized_by |
gptkb:World_Health_Organization
|
| gptkbp:is_studied_in |
neurology
|
| gptkbp:is_supported_by |
non-profit organizations
|
| gptkbp:known_as |
gptkb:Lou_Gehrig's_disease
gptkb:amyotrophic_lateral_sclerosis |
| gptkbp:life_expectancy_after_diagnosis |
3 to 5 years
|
| gptkbp:lifespan |
3 to 5 years after diagnosis
|
| gptkbp:notable_person |
gptkb:Stephen_Hawking
gptkb:Lou_Gehrig |
| gptkbp:notable_quote |
" The only thing I can do is to keep going."
" I have lived with the prospect of death for a long time." |
| gptkbp:prevalence |
2 per 100,000 people
|
| gptkbp:public_awareness |
gptkb:June
|
| gptkbp:research_focus |
gptkb:gene_therapy
stem cell therapy |
| gptkbp:research_is_ongoing_for |
new treatments
|
| gptkbp:symptoms |
respiratory failure
difficulty speaking muscle weakness difficulty swallowing muscle atrophy muscle cramps twitching muscles |
| gptkbp:treatment |
gptkb:riluzole
gptkb:edaravone improving quality of life symptom management prolonging life |
| gptkbp:bfsParent |
gptkb:Stephen_Hawking
|
| gptkbp:bfsLayer |
3
|